Fortrea (FTRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$17.70-4.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FTRE
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 5 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $18 FTRE trades at 30× p/e — 1.3× the 22× p/e peer median. The market is re-rating it beyond its own range; our $17 fair value is medium-confidence here. Analysts target $16–$23. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $20.00 | — | — | Analyst | high |
| Peer P/FCF | 12M | $34.29 | 21.6 | 1.59 | TTM | high |
| Peer P/E | 12M | $18.36 | 17.6 | 1.04 | ntm analyst | high |
| PEG | 12M | $8.40 | 14.0 | 0.60 | TTM | high |
| triangulated | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$16.00 – $23.00 (median $20.00) · 5 analysts · as of 2026-07-30
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $12.53 |
| 22.0 |
| 0.57 |
| Triangulated |
| high |
| Peer P/FCF | 3Y | $26.33 | 21.6 | 1.22 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $17.33 | 17.6 | 0.98 | Analyst | medium |
| PEG | 3Y | $12.77 | 14.0 | 0.91 | Analyst | medium |
| Peer P/FCF | 5Y | $22.08 | 21.6 | 1.02 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $16.35 | 17.6 | 0.93 | Analyst | medium |
| PEG | 5Y | $16.89 | 14.0 | 1.21 | Analyst | medium |